Mucopolysaccharidosis type I (MPS-I; Hurler syndrome) is an inborn error of metabolism caused by lack of the functional lysosomal glycosaminoglycan (GAG)-degrading enzyme α-L-iduronidase (IDUA). Without treatment, the resulting GAG accumulation causes multisystem dysfunction and death within the first decade. Current treatments include allogeneic hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy. HSCT ameliorates clinical features and extends life but is not available to all patients, and inadequately corrects the most devastating features of the disease including mental retardation and skeletal deformities. Recent developments suggest that stem cells can be used to deliver needed enzymes to the central nervous system. To test this concept, we transplanted bone marrow-derived normal adult human MultiStem cells into the cerebral lateral ventricles of immunodeficient MPS-I neonatal mice. Transplanted cells and human-specific DNA were detected in the hippocampal formation, striatum, and other areas of the central nervous system. Brain tissue assays revealed significant long-term decrease in GAG levels in the hippocampus and striatum. Sensorimotor testing 6 months after transplantation demonstrated significantly improved rotarod performance of transplanted mice in comparison to nontransplanted and sham-transplanted control animals. These results suggest that a single injection of MultiStem cells into the cerebral ventricles of neonatal MPS-I mice induces sustained reduction in GAG accumulation within the brain, and modest long-term improvement in sensorimotor function.
INTRODUCTION
donor-derived microglia. Also, HSCT does not provide trophic/chaperone neuroprotective effects on diseased or damaged host neurons (12, [56] [57] [58] [59] . Amelioration of neu-Mucopolysaccharidosis type I (MPS-I; Hurler syndrome) is caused by a deficiency of the lysosomal rocognitive and adaptive functions (communication, daily living skills, socialization, and motor function) is glycosaminoglycan (GAG)-degrading enzyme α-L-iduronidase (IDUA) (37). Progressive neuropsychological therefore inadequate; stabilization or slower than normal improvement occurs, largely restricted to younger deterioration is one of the most devastating manifestations of this disease (32, 60) . Allogeneic hematopoietic patients who have better baseline cognitive function and achieve stable long-term engraftment (6, 43, 52) . Enzyme stem cell transplantation (HSCT) provides IDUA, clears accumulated GAGs, and markedly improves survival replacement therapy (ERT) cannot improve neurological function since IDUA does not cross the blood-brain bar- (36, 41, 42, 45, 52) . However, GAG clearance from the brain is incomplete since it depends on the central ner-rier (25, 36) . Novel cellular therapeutic approaches directed at the CNS (31) are therefore needed, both as vous system (CNS) penetration of small numbers of an adjunct to allogeneic HSCT or ERT, and for patients trials in acute myocardial infarction, ischemic stroke, and allogeneic HSCT (8, 33) . unable to receive a HSCT. Such approaches need evaluation in animal models of MPS-I (13, 20) . We recently
We hypothesized that intracerebroventricular (ICV) transplantation of MultiStem cells may provide IDUA confirmed that an immunodeficient mouse model of MPS-I [non-obese diabetic/severe combined immunode-in the brain and trophic/chaperone neuroprotective effects in MPS-I. The ICV route was used because it has ficient (NOD/SCID)/MPS-I] exhibits the biochemical and pathological features of human Hurler syndrome, the potential to (a) achieve widespread distribution of the transplanted cells, (b) provide transplanted cells in including abnormalities in sensorimotor function and training (17). We and others showed that the immunode-the meninges, wherein extensive GAG accumulation occurs and results in hydrocephalus in MPS-I, and (c) ficient background makes this model suitable for transplantation with human (xenogeneic) mesenchymal be clinically applicable to the treatment of patients in the future. The effect of transplantation was tested in stromal cells (MSCs) (35) and gene therapy (3, 13, 44) .
Pioneering work from Snyder and colleagues on neonatal mice since (a) the microenvironment of the brain is more conducive to stem cell survival and prolif-intracranial transplantation of murine (51) and fetal human neural stem cells (NSCs) (28) in animal models eration at an early age, and (b) neuropathology has not yet developed at this age, nor has meningeal accumula-of lysosomal storage diseases (LSDs) provided compelling proof of principle of the enormous potential of cel-tion of GAGs causing restriction of cerebrospinal fluid flow that might impair the distribution of transplanted lular therapy directed at the CNS. Recent studies from our group identified a different type of multipotent pro-cells. Further, the strategy used here will be more applicable towards future clinical use as it will be ideal to genitor cell in postnatal (adult) human and mammalian bone marrow. Such cells grow without senescence perform transplantation prior to the development of irreversible neuropathology and neurobehavioral deficits (22, 23, 26, 63, 64) , expand sufficiently for clinical use in humans (40), differentiate into cells representing all in patients. This is the first report of the biochemical and func-three embryonic layers including neuronal cells (4, (21) (22) (23) 26) , maintain genetic stability and telomere length tional effects of transplanting adult human bone marrow-derived multipotent (MultiStem) cells into the (8) , and exhibit an epigenetic profile and differentiation potential more primitive than MSCs (1, 8) . We showed cerebral lateral ventricles of neonatal immunodeficient MPS-I mice. that normal human bone marrow-derived multipotent stem cells (similar to the MultiStem cells used in the MATERIALS AND METHODS current study) secrete sufficient IDUA to cross-correct Animals GAG accumulation and metabolism [correction of abnormal size (M r 5 kDa, vs. normal size being 42 kDa) Approval for all studies performed with animals was obtained from the Institutional Animal Care and Use and sulfation pattern of heparan sulfate] in bone marrow-derived multipotent stem cells cultured from the Committee (IACUC) of the University of Minnesota. Immunodeficient NOD.129(B6)-Prkdc scid Idua tm1Clk /J mice marrow of patients with Hurler syndrome (19).
In vivo, we and others showed that these types of heterozygous for the IDUA mutation were purchased from The Jackson Laboratory (Bar Harbor, ME). Het-cells [rodent/human MSCs as well as multipotent adult progenitor cells (MAPCs; similar to MultiStem cells)] erozygous mice were mated, producing approximately 20-25% homozygous NOD/SCID/MPS-I (IDUA −/− ) exert beneficial trophic/chaperone and immunomodulatory effects following transplantation in animal models mice (termed MPS-I hereafter), 50% heterozygous (IDUA +/− ) mice (termed Ht), and 25% wild-type (IDUA +/+ ) of various diseases [reviewed by Auletta et al. (4) ]. Human multipotent stem cells differentiate into various offspring (termed WT). Mating of MPS-I males with Ht females, when successful, produced a higher proportion lineages and induce functional improvement in peripheral vascular ischemia in mice (2) , and neurological of MPS-I offspring. We have recently described the biochemical, phenotypic, and behavioral characteristics of improvement in rat models of cerebral ischemia (33, 63) and traumatic brain injury (55) . Importantly, adult this mouse model of MPS-I (3, 17) . Mice were genotyped using tail clip samples, as human multipotent stem cells can easily be obtained from bone marrow aspirates and expanded rapidly in described previously (17), according to the protocol on The Jackson Laboratory website (http://jaxmice.jax.org/ vitro, and are unencumbered with ethical concerns associated with human embryonic stem (ES) cells or fetal strain/004083.html). The following primers were used: forward oIMR 1451 (5′-GGAACTTTGAGACTTGG NSCs. Such cells [MultiStem; expanded under good manufacturing practice (GMP) conditions by Athersys AATGAACCAG-3′); WT reverse oIMR 1452 (5′-CATT GTAAATAGGGGTATCCTTGAACTC-3′); MPS reverse Inc., Cleveland, OH] are currently in phase I clinical oIMR 1453 (5′-GGATTGGGAAGACAATAGCAGG by each animal was achieved under a heating lamp. Once fully awake, the pups were returned to their par-CATGCT-3′). PCR products were resolved on a 1.5% agarose gel. Genotype assignment of individual animals ents. Genotyping was performed after weaning at 3 weeks of age. Since the genotype was not known at the was confirmed by repeating genotyping on tissue samples obtained at euthanasia. time of transplantation, we randomly chose one to two neonates/litter as negative controls for injecting the 3 µl A total of 80 mice contributed to the data included in the current article. Fourteen neonates were sacrificed at of PBS alone (sham transplantation). This also ensured that all genotypes of mice, including the MultiStem cell-varying periods (from immediately after transplantation to 2 weeks after transplantation) for immunofluores-transplanted and sham-transplanted mice, were littermates. The individuals performing the genotyping, cence staining of the brain (shown in Figs. 1 and 2 ). Sixty-six mice were used for the other studies and behavioral tests, immunohistochemistry, biochemical measurements, and behavioral tests were blinded to the assays; these included 18 WT, 10 Ht, and 38 MPS animals; 58% were males.
identity of the sham-transplanted mice; this was only disclosed at the time of data analysis.
ICV Transplantation of MultiStem Cells
Complications of the transplantation procedure included abscess formation on the head for which seven Transplantation was performed on neonatal mice between postnatal days 3 and 6. One day prior and 1, 4, mice were sacrificed. Histopathological examination identified these as Staphylococcal in etiology. Two of 7, and 11 days following transplantation, all neonates received an anti-natural killer (NK) cell antibody (10 µl/ these mice had received sham transplants (PBS injection), making it unlikely that the abscesses were related g body weight IP, anti-asialo GM1, cat. #986-10001, Wako Pure Chemical Industries Ltd., Osaka, Japan) to to MultiStem cells themselves or to contamination of the cell product. There were several instances of the mothers enhance MultiStem cell survival in vivo. Previous studies have shown that mice of this immunodeficient cannibalizing the transplanted neonates (three litters, and sporadic additional mice), resulting in loss of those ani-(NOD/SCID) background can develop NK cell-mediated rejection of transplanted stem cells, which can be mals for subsequent analysis. Of note, human MultiStem cells were not identified in any of the tumors (e.g., thy-ameliorated by peritransplant administration of NK cellblocking antibodies (34, 48) . momas) that are known to develop in these immunodeficient mice, or teratomas that are associated with Human MultiStem cells were obtained in frozen aliquots from Athersys Inc. (Cleveland, OH). Immediately embryonic stem cells. before transplantation, cells were thawed, centrifuged in Immunohistochemistry sterile PBS to remove dimethyl sulfoxide (DMSO), counted and evaluated for viability using trypan blue
To evaluate survival and distribution of transplanted MultiStem cells, some mice were sacrificed at different exclusion, and resuspended in PBS. A midline incision was made in the disinfected skin of the scalp, which was intervals after transplantation. Animals were studied for histology immediately after injection and at 1, 3, 7, and then retracted bilaterally, exposing the external auditory orifices to facilitate placement of ear bars. The maxilla 14 days after injection, or at the end of the study following behavioral testing (about 24 weeks). was set on a tooth bar, immobilizing the head in a Kopf head holder. The neonate's body was then placed on tin For neonates 1-5 days of age, animals were anesthetized by hypothermia or with ketamine/xylazine admin-foil kept on top of a bed of ice. Stereotactic injection was performed to target the right lateral cerebral ventri-istration for animals greater than 5 days of age, and then decapitated. Brains were then taken out and immersed cle. A hole was made on the skull (coordinates: 0.0 mm anterior, 0.5 mm right lateral to bregma). Since no bony in 4% ice-cold paraformaldehyde for 24 h, replaced with 30% sucrose for at least 48 h or until the brains sank to markers form at this age, orientation was achieved by visualization of the juncture of several cartilages under the bottom. These brains were cut on a microtome, 30 µm in thickness. the surgical microscope. A Hamilton needle attached to a syringe loaded with 100,000 MultiStem cells in 3 µl
For adult mice at the end of the experiment (about 24 weeks), all mice were anesthetized with injection of PBS was introduced 1.8 mm deep from the cortex. After waiting for 1 min, the cell suspension was injected into ketamine/xylazine mixture, a transcardial perfusion was performed with ice-cold PBS, brains were cut in half the right lateral cerebral ventricle using a micropump (Convection Enhanced Device) at a rate of 0.5 µl/min. longitudinally, right hemispheres (injection side) were immersed in 4% paraformaldehyde for 24 h of fixation, The needle was kept in place for another 2 min to minimize leakage and help diffusion of injected cells in ven-and placed in 30% sucrose until they were cut with a microtome. For biochemical studies the left hemispheres tricular system. The wound was then closed and recovery were kept on a bed of ice after removal from the skull, from the PCR reaction was confirmed to be of the correct size on gel electrophoresis. and with the aid of a surgical microscope, the striatum, hippocampus, cortex, cerebellum, and rest of the brain Measurement of GAG Levels and IDUA Activity were dissected and immediately flash frozen and stored at −80°C for subsequent use in endogenous retrovirus-3 GAG levels and IDUA enzyme activity were deter-(ERV-3) real-time quantitative PCR, GAG quantificamined in flash-frozen brain tissue samples from transtion and IDUA assays.
planted, untransplanted, and sham-transplanted mice. The For immunohistochemistry, brain sections were rinsed methods used were as described by us previoiusly (17). with PBS, blocked with 5% normal donkey serum GAG Content. Proteins in clarified supernatants of (NDS) + 0.3% Triton X-100 in PBS (blocking medium) brain homogenates were removed by digestion with Profor 1 h at room temperature, then incubated with mouse teinase K, and nucleic acids by DNase + RNase. GAG anti-human nuclei (Millipore, Temecula, CA, Mab 1281, concentration was determined using the Blyscan Sul-1:100) in blocking medium at 4°C overnight, followed fated Glycosaminoglycan Assay (Accurate Chemical & by a PBS wash, then incubated with AlexaFluor 488 Scientific Corp., Westbury, NY), and expressed as µg donkey anti-mouse IgG (Invitrogen, Carlsbad, CA, A-GAG/mg protein. 21202, 1:500) + DAPI (Sigma, USA, D9542, 1:500) in IDUA Activity. Brain samples were homogenized in blocking medium for 1 h at room temperature, followed 1 ml PBS, then treated with 11 µl of 10% Triton X-100 by a final PBS wash. Stained sections were mounted and in PBS on ice for 10 min. Protein concentration in the cover-slipped. Tissue sections were examined using a supernatant was estimated using the Bradford method, Nikon microscope (ECLIPSE E600) and images were and IDUA activity assayed according to In addition, for measuring IDUA activity, normal isolated from the frozen brain samples using the Qiagen human MultiStem cells and HEK293T human embry-DNeasy Blood and Tissue kit. Care was taken to avoid onic kidney cells were cultured in T-75 tissue culture human contamination during DNA purification by using flasks. MultiStem cells (obtained frozen from Athersys) aerosol barrier pipette tips and tubes certified to be free were thawed and plated for a few days in 54% DMEM of human DNA. Human DNA was detected by real-time (Invitrogen) + 40% MCDB (Sigma) supplemented with quantitative PCR using primers specific for ERV-3, an 2% fetal bovine serum (FBS), penicillin/streptomycin, endogenous retrovirus found in the human genome but 1× insulin-transferrin-selenium, 100 µM ascorbic acid, not in rodents (29) . The real-time PCR reaction con-55 µM β-mercaptoethanol, and 5 ng/ml each of platelettained 50 ng DNA with 0.4 mM of each primer (forward derived growth factor (PDGF)-BB (R&D Systems, Min-ERV-3 primer: 5′-atgggaagcaagggaactaat and reverse neapolis, MN) and epidermal growth factor (Sigma). ERV-3 primer: 5′-cccagcgagcaatacagaattt) and Invitrogen's HEK293T were cultured in DMEM supplemented with Platinum SYBR Green qPCR supermix. The following 10% FBS, penicillin/streptomycin, 4 mM glutamine, 1 PCR profile was performed on an Applied Biosciences mM sodium pyruvate, and 1.5 mg/ml sodium bicarbon-7900HT Fast Real Time PCR thermocycler: 50°C for 2 ate. When the cells were nearly confluent, media were min, 95°C for 10 min, and then 45 cycles of denaturreplaced by PBS + 0.1% BSA. After overnight incubaation at 95°C for 15 s and annealing at 58°C for 1 min. tion, IDUA activity was separately assayed in the super-A final dissociation step of 95°C for 15 s, 60°C for 15 natant and in the cell lysates. s, and 95°C for 15 s concluded the amplification. A standard curve was generated using serial dilutions of RotaRod Test for Sensorimotor Function human MultiStem cell DNA mixed with mouse brain DNA. PCR products were resolved on a 2% agarose gel Sensorimotor function was tested using a Rotarod machine (Model 8200 LSi Letica, PANLAB, Spain). to confirm the correct product size. Individual samples of the brains were classified as being positive if the Ct
The rotarod test measures sensorimotor function and coordination (14) . We have previously validated in this value was <40 cycles on real-time PCR, and the product mouse model (17) and in another mouse model (24) that injection site, MultiStem cells were observed near the hippocampal formation and habenula ( Fig. 1G-O) . One the range of rotarod speeds used in this study (5-25 rpm) is appropriate, tests the range of sensorimotor abil-day after transplantation, transplanted cells were still found near the hippocampal formation and 3rd ventricle ity, and identifies motor abnormalities. It is important to test a range of speeds, since, as shown in the present ( Fig. 1P-X) . In some instances clusters of cells appeared to be integrating with the ependymal cells ( Untransplanted/sham-transplanted WT, Ht, and MPS-2A-I). These cells also appeared to be penetrating through the ependymal layer. Three days after transplan-I mice, as well as MultiStem cell-transplanted MPS-I mice were tested using the procedure described by us tation, MultiStem cells were found integrated within the brain parenchyma dorsal to the lateral cerebral ventricle previously (17), for 5 sequential days immediately prior to sacrifice at approximately 24 weeks of age. The per-( Fig. 2J-L) . By day 14 grafted cells could be observed in the habenula near the 3rd ventricle ( Fig. 2M-R) . In formance of untransplanted/sham-transplanted WT mice was equivalent to that of Ht mice; therefore, these two general MultiStem cells were easily detected within the brain up to 1 week posttransplantation, but their pres-genotypes were grouped together as the control cohort for the rotarod test. The mean ages of the controls, ence began to diminish thereafter. untransplanted/sham-transplanted MPS-I mice, and
Survival of Human MultiStem Cells in the Mouse Brain MultiStem cell-transplanted MPS-I mice were 16 ± 0.7, 18 ± 1.6, and 22 ± 1.0 weeks, respectively. Differences ERV-3 is an endogenous retrovirus incorporated into the human genome but not in the genomes of rodents. in ages were not statistically significant except for the MultiStem cell-transplanted MPS-I mice being older Detection and enumeration of ERV-3 copies by realtime quantitative PCR therefore provides a sensitive than the control cohort (p < 0.0001). Day 1 of testing established a baseline of sensorimotor function in each method to detect and quantitate low levels of transplanted human cells surviving in the mouse brain (29) . animal. Improvement in balance time over 5 repetitive days of testing provided a measure of the ability of indi-In control samples used to generate a standard curve ( Fig. 3A) , ERV-3 could consistently be detected down vidual mice to improve their sensorimotor functioning with training.
to a dilution of 0.0125% human MultiStem cell DNA in mouse brain DNA. Thus, this method was capable of Statistical Analysis detecting about 1 human genome (cell) in 8,000 mouse Data were analyzed using GraphPad Prism 5.0 softgenomes (cells). Figure 3B shows one representative ware (GraphPad Software Inc., San Diego, CA). Results image of gel electrophoresis that was performed on all were expressed as mean ± SE. The significance of dif-PCR products and appropriate controls to confirm the ferences in GAG level between groups was examined presence of an ERV-3 product of the correct size. The using one-way ANOVA. Rotarod test results were evaltable in Figure 3C shows the frequency of detection of uated and compared using two-way repeated measures ERV-3 (indicative of surviving human MultiStem cells) Model I ANOVA. The subject (matching) p-values were in microdissected regions of sham-and MultiStem celllow for all comparisons (all p < 0.002), indicating that transplanted mice, sacrificed approximately 24 weeks the repeated measures design was appropriate and was after transplantation. As expected, ERV-3 was not effective in controlling for variability between mice. The detectable in sham-transplanted mice. In contrast, ERV-Tukey-Kramer posttest was used with ANOVA.
3 was detected with variable frequency in the brains of MultiStem cell transplanted WT, Ht, and MPS-I mice.
RESULTS
Overall, ERV-3 was detected somewhat more frequently Distribution of Human MultiStem Cells Transplanted in the hippocampus and striatum, compared to the cere-Into the Mouse Brain bral cortex and cerebellum. The level of long-term (24 weeks) engraftment and survival of human cells was Immediately after transplantation and at various posttransplant time periods some mice were sacrificed to quite variable, but <0.1% in most samples where human DNA was quantifiable (Fig. 3D) . These results suggest determine the distribution of the MultiStem cells within the brain. MultiStem cells were identified using an anti-that small numbers of human MultiStem cells survive for at least 24 weeks following ICV transplantation into body that recognized human cells (MAb 1281). Immediately after transplantation, MultiStem cells were observed neonatal immunodeficient (NOD/SCID) mice, irrespective of the presence or absence of host IDUA. Human predominantly in the cerebral lateral ventricles near the injection site, striatum, and medial septum in the 4th cells appeared to survive somewhat more often in the same regions of the brain (Fig. 3) , which demonstrated ventricle ( Fig. 1A-F) . At more distal regions from the significant clearance of accumulated GAGs (hippocam-secrete the enzyme. IDUA activity (9.956 ± 0.238 nmol/ h/mg protein) was present in the lysates of MultiStem pus and striatum) ( Fig. 4) . However, a direct correlation of ERV-3 with GAG clearance could not be determined cells in culture, and was detectable in the culture supernatant (0.189 ± 0.003 nmol/h/ml) of these cells har-since the ERV-3 PCR could not be performed on all the samples in which GAGs were measured.
vested after overnight incubation. Enzyme activity in the lysates and supernants of MultiStem cells was substan-Reduction in GAG Accumulation in the Brains tially greater than IDUA activity in HEK293T cells of Transplanted MPS-I Mice (lysates: 0.228 ± 0.007 nmol/h/mg protein and culture GAG concentration was measured in the hippocamsupernatant: 0.011 ± 0.001 nmol/h/ml). pal formation, striatum, cerebellum, cortex, and the As expected, IDUA activity was undetectable in the remainder of the brains of sham-transplanted or Multibrains of untransplanted MPS-I mice. At 24 weeks after Stem cell-transplanted WT, sham-transplanted or untranstransplantation of MPS-I mice with human MultiStem planted MPS-I mice, and MPS-I mice-transplanted with cells, IDUA activity was undetectable in the brain. The human MultiStem cells (Fig. 4) . GAG levels were siglack of IDUA activity in transplanted MPS-I mice may nificantly elevated in all regions of the brains of untransindicate that enzyme levels have fallen below the level planted or sham-transplanted MPS-I mice compared to of detection of the assay at 24 weeks after transplanta-WT mice (p < 0.001 for all regions of the brain). ICV tion, consistent with the loss of most of the transplanted transplantation of human MultiStem cells into neonatal cells by this time. MPS-I mice resulted in a statistically significant longterm (at ϳ24 weeks) decrease of GAG levels in the hip-Improvement in Sensorimotor Function pocampus, striatum, and remaining brain. The slight
In males, the rotarod test demonstrated significant reduction in GAG levels in the cortex and cerebellum improvement in sensorimotor function ( Fig. 5A-D) in did not reach statistical significance.
MPS-I mice that received transplants of MultiStem cells. Long-term amelioration of GAG accumulation in the At 5 rpm. The performance of all three groups hippocampus and remaining brain was partial, since (untransplanted/sham-transplanted WT and Ht, untrans-GAG levels in these regions in transplanted MPS-I mice planted/sham-transplanted MPS-I, and MultiStem celldid not completely return to WT GAG levels. Interesttransplanted MPS-I mice) improved consistently and ingly, however, GAG levels in the striatum of transsignificantly on sequential days of testing (p < 0.0001), planted MPS-I mice became comparable to those of the but to a comparable extent; that is, at this low speed, the WT animals (p > 0.05).
performance of untransplanted/sham-transplanted MPS-I mice was not inferior to that of untransplanted/sham-Iduronidase Enzyme Activity in MultiStem Cells transplanted WT and Ht mice and that of MultiStem and in the Mouse Brain cell-transplanted MPS-I mice (significance of interaction We have previously shown that human bone marrowbetween sequential days of testing and groups of mice: derived multipotent progenitor cells secrete functional p > 0.05).
IDUA that cross-corrects similar cells obtained from the bone marrow of patients with Hurler syndrome (19). We
At 15 rpm. The performance of all three groups of mice improved significantly on sequential days of test-now confirm that the MultiStem cells used for the transplantation studies reported here also synthesize and ing (p < 0.002). There was no significant interaction cell transplanted MPS-I mice: p = 0.0264), with mouse groups accounting for a greater percentage of the total At 25 rpm. At this high speed, the performance of MultiStem cell-transplanted MPS-I mice on sequential variation than interaction or days of testing. Of note, at both 15 and 25 rpm, the performance of MultiStem cell-days of testing was significantly better than that of untransplanted/sham-transplanted MPS-I mice (signifi-transplanted MPS-I mice became comparable to that of untransplanted/sham-transplanted WT and Ht mice. cance of interaction between sequential days of testing Effect of Training. The response of mice to training was tested by evaluating the improvement in performance (increase in balance time) by the fifth consecutive day of testing. The results obtained in the three groups of mice tested at 25 rpm (Fig. 5C ) showed that untransplanted/sham-transplanted MPS-I mice were essentially unable to improve their performance over the 5 days. In contrast, the ability of MultiStem cell-transplanted MPS-I mice to improve with training became comparable to that of the untransplanted/sham-transplanted WT and Ht mice. By the fifth day of repetitive practice on the test (Fig. 5D ), the MultiStem cell-transplanted MPS-I mice were able to perform the task as well as untransplanted/sham-transplanted WT and Ht mice and remain balanced on the rotarod for comparable lengths of time at 5, 15, and 25 rpm. In contrast, the untransplanted/sham-transplanted MPS-I mice demonstrated a steep drop off in balance time at increasing speeds. The difference between the performance of MultiStem cell-transplanted MPS-I and untransplanted/ sham-transplanted MPS-I mice (Fig. 5D ) was highly significant, and largely attributable to interactions between rotarod speed and the two groups of mice (significance of interaction between rotarod speed and MultiStem cell-transplanted MPS-I vs. untransplanted/sham-transplanted MPS-I mice: p = 0.0061). These results indicate that the inability of untransplanted/sham-transplanted MPS-I mice to perform at the more challenging speeds, and to improve their sensorimotor ability with training, was completely corrected following ICV transplantation of MultiStem cells.
DISCUSSION
Since the seminal report of ICV implantation of murine NSCs in neonatal MPS-VII mice (51), several FACING COLUMN Figure 5 . Improvement in sensorimotor function. Mice were tested on the rotarod apparatus for 5 sequential days immediately prior to sacrifice at approximately 24 weeks of age. The time for which male mice were able to stay balanced on a rod rotating at different speeds is shown as the mean ± SE in seconds. Untransplanted Fig. 3 ). studies [reviewed by Singec et al. (50) ] showed the Our study is the first to examine the effect of ICV implantation of adult human MultiStem cells in a mouse remarkable potential of various types of murine cells, implanted directly into the brain or cerebral lateral ven-model of MPS. Within a few days, MultiStem cells migrated widely into the brain parenchyma and underwent tricles, to engraft, migrate, acquire neural markers, and induce biochemical, pathological, and functional early proliferation, and even though cell survival dropped off steeply over time, implantation at the neonatal stage improvement in rodent models of MPS and other neuropathic LSDs.
induced long-term improvement in substrate (GAG) levels and neurological functioning. No obvious adverse effects Clinical application, however, will require the use of rigorously evaluated human cells (31) . Towards this were identified from MultiStem cells implantation. We found that reduced GAG levels in the hippocam-goal, recent studies (summarized in Table 1 ) examined the effect of implanting human cells into the brain or pus and striatum were associated with improved motor coordination and response to training. Motor coordina-cerebral ventricles of mouse models of neuropathic LSDs including one report in MPS-IIIB, but not in tion, measurable by the rotarod and other tests (17,62), is impaired in mouse models of MPS-I. This could be MPS-I. The results of implanting human umbilical cord blood (UCB) cells, ES-like cells, MSCs, or NSCs were a consequence of MPS-induced dysfunction of multiple organ systems including the brain, the skeletal system, variable. Garbuzova-Davis et al. (16) were the first to show that a proportion of UCB mononuclear cells and vestibular and visual pathways. However, since functioning of the latter three systems does not change implanted intracerebroventricularly into 1-month-old MPS-IIIB mice survived for an extended period (7 during repetitive testing, it can be inferred that serial rotarod testing accurately measures neurological perfor-months), migrated widely into the parenchyma, and acquired neural markers and morphology; quantitative mance relating to motor coordination (17). As expected, control (untransplanted) MPS-I mice demonstrated sig-estimates of GAG clearance and enzyme activity in the brain and evaluation of neurological functional were not nificant impairment of their ability to improve with training on serial rotarod tests. In contrast, the perfor-provided. In a subsequent report, the authors reported that intravenous transplantation of UCB cells improved mance curve of MultiStem-transplanted MPS-I mice improved and approximated that of WT and Ht animals. behavioral outcomes in murine MPS-IIIB (15) . Croitoru-Lamoury et al. (11) reported that embryonal carcinoma No significant abnormality in sensorimotor functioning in MPS-I mice was discernible at the slowest speed (5 (ES-like) cells or marrow-derived MSCs survived for up to 5 weeks and acquired markers of neural differentia-rpm), which may have been too slow to demand the animals' full attention to the task, since many mice deliber-tion, but did not induce functional benefit in a mouse model of Krabbe's disease. Information on substrate/ ately jumped off the rod or turned around and attempted to walk backwards at 5 rpm. On the other hand, the metabolite clearance and enzyme activity was not provided. Snyder and colleagues examined the effect of highest speed (35 rpm) was too challenging, since none of the cohorts of mice were able to remain on the rod implanting human NSCs: Taylor et al. (54) demonstrated that primary fetal NSCs implanted into a mouse for a reproducible period of time. Previous work showed that survival of adult human model of Krabbe's disease survived and acquired oligodendrocytic markers. Lee et al. (28) reported that pri-progenitors implanted in the rodent brain is considerably less sustained and robust than that of fetal NSCs. Azizi mary fetal NSCs or ES cell-derived NSCs engrafted robustly and survived for up to 22 weeks in a mouse et al. (5) reported that survival of adult human MSCs implanted into the striatum of partially immunodeficient model of Sandhoff disease. These cells migrated widely, acquired neural markers, secreted effective levels of rats declines after 1 month. We recently reported that the majority of human MultiStem cells implanted intra-enzyme, and induced substrate clearance and functional improvement. In contrast, using a different NSC line, cerebrally into ischemic rat brains are lost within 72 h; only 1% survive for 2 months (33). The current results Sidman et al. (49) reported that implanted NSCs were undetectable at 16 weeks, and even though there was with MultiStem cells are consistent with these previous reports. Our results are consistent with previous reports some substrate clearance, there was no functional improvement in a mouse model of Niemann-Pick A dis-where immunosuppression did not augment survival or functional benefit of rat or human MultiStem cells ease. These reports indicate that variability in outcome of intracranial cell transplantation is related to the under-injected either into the brain or intravenously in neonatal and adult rats (33, 61) . lying disease, type of cells used, timing, and site of transplantation. The effects of intracranial implantation How might GAG clearance and functional improvement have been achieved without long-term survival of of human NSCs in animal models of MPS remain to be determined. These aspects are relevant to clinical advance-large numbers of transplanted cells? A consistent theme emerging from evaluation of cell therapy in various ment of intracranial cell transplantation strategies.
diseases is that functional improvement occurs in the following hypoxic-ischemic brain injury, transplantation of rat MultiStem cells into the hippocampus of neonatal absence of robust replacement of host tissue cells by differentiated transplanted cells (10, 18, 39, 50) . This rats improved endogenous neuronal survival and neurological functioning at 2 weeks (61, 62) . Even though apparent paradox is explained by increasing recognition of a multifaceted trophic/chaperone effect of trans-≤1% transplanted cells survived, transplantation was associated with significant (>20%) increase in survival planted cells in injured/dysfunctional host organs (50) . Indeed, we have observed an inverse relationship of host neurons in the CA3 region of the hippocampus. Interestingly, rat MultiStem cells injected intravenously between long-term survival of human MultiStem cells and trophic protection of endogenous neurons in a rat also homed to the hippocampus of these animals, suggesting that the hippocampus provides both migratory/ cerebral ischemia model: earlier transplantation rescued more neurons injured by acute ischemia even though homing cues such as stromal-derived factor-1 (SDF-1) and a microenvironment supportive of the survival of fewer MultiStem cells survived in the acute ischemic brain (33) .
transplanted cells. Early improvement (at 2 weeks) suggested that the effect was a result of a trophic/chaperone We speculate that several complementary mechanisms of action may have contributed to the long-term effect of MultiStem cells on injured host neurons and/or NSCs, rather than differentiation of MultiStem cells into functional improvement seen in our study. One possibility is that robust short-term survival and extensive early neural cells. Using human MultiStem cells, we reported similar findings in an adult rat cerebral ischemia model migration of transplanted MultiStem cells provides sufficient IDUA to clear GAGs and prevent/slow their (33) . Similarly, we previously showed that human multipotent stem cells implanted around an area of cerebral usual rate of accumulation in the brains of MPS-I mice; this "resets" the quantity of GAGs in the brain to a lower ischemia in adult rats migrated, acquired neural markers (but not morphology) and reduced neurological deficits level, which then results in the quantity of GAGs being lower than in control (untransplanted) animals even after (63). Functional improvement in all these studies was most likely the result of the neuroprotective trophic/ several months, despite gradual resumption of GAG accumulation with the longer term decline in MultiStem chaperone effect (50) of implanted cells on injured host neuronal cells, without actual replacement of lost neu-cell number. By 24 weeks, few MultiStem cells survive, insufficient to provide detectable levels of IDUA. How-rons by multipotent cell-derived progeny. Finally, it is possible that MultiStem cell-induced ever, early clearance of GAGs [together with perhaps a trophic/chaperone effect (50) of the MultiStem cells: immunomodulation (4,55) may reduce the damaging neuroinflammation that occurs in MPS (27,38). The discussed below] provides some degree of protection from neurological damage in the critical early postnatal existence and contribution of these various mechanism(s) is currently under study. developmental phase (59) ; this may be of sufficient magnitude to achieve sustained improvement in sensorimotor function up to at least 24 weeks. A similar effect CONCLUSIONS AND FUTURE DIRECTIONS has been reported following HSCT in feline MPS-I, where reduction in GAG accumulation in the brain and MultiStem cell transplantation merits further evaluation as a therapy for neurobehavioral abnormalities improvement in mobility occurred in the absence of increase in IDUA activity in the brain (12). associated with MPS-I and other neuropathic disorders. While our study provides proof of principle of Secondly, it is known that endogenous NSC proliferation is reduced in mouse models of MPS (30) . The hip-the potential therapeutic efficacy of these cells in MPS-I, clinical applicability will require further pocampus, which plays a critical role in learning and memory, is a site of ongoing neurogenesis in the early enhancement of cell survival, augmentation of enzyme secretion (perhaps by IDUA gene transduction), iden-postnatal period. It is possible that transplanted Multi-Stem cells that migrate into the hippocampus following tification of the molecular and cellular mechanism(s) of action of these cells and control of their behavior ICV injection provide a trophic/chaperone effect that improves survival and/or proliferation of endogenous in the brain, and comparative evaluation against human fetal NSCs (7,28), UCB cells (15, 16) , men-NSCs during the critical neonatal period. This may contribute to improvement in training ability that is main-strual blood-derived progenitors (9, 46) , and other postnatal progenitors with neurogenic potential such tained even after the subsequent loss of most transplanted MultiStem cells.
as induced pluripotent stem (iPS) (53) and NurOwn (18) cells. Finally, this strategy will need to be tested Thirdly, MultiStem cells may exert neuroprotective effects in MPS-I, including a trophic/chaperone effect on in the settings of HSCT or ERT that are essential for treating the systemic manifestations of MPS-I and the survival of host postmitotic neurons, as we have shown in cerebral ischemia (63). We have also demonstrated that, other lysosomal storage diseases. 
